ATE366121T1 - Systemische verabreichung von serum-stabilen plasmid-lipid partikeln zur krebstherapie - Google Patents

Systemische verabreichung von serum-stabilen plasmid-lipid partikeln zur krebstherapie

Info

Publication number
ATE366121T1
ATE366121T1 AT99903557T AT99903557T ATE366121T1 AT E366121 T1 ATE366121 T1 AT E366121T1 AT 99903557 T AT99903557 T AT 99903557T AT 99903557 T AT99903557 T AT 99903557T AT E366121 T1 ATE366121 T1 AT E366121T1
Authority
AT
Austria
Prior art keywords
serum
cancer therapy
systemic administration
lipid particles
stable plasmid
Prior art date
Application number
AT99903557T
Other languages
English (en)
Inventor
Ian Maclachlan
Roger Graham
Original Assignee
Protiva Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27535971&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE366121(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Protiva Biotherapeutics Inc filed Critical Protiva Biotherapeutics Inc
Application granted granted Critical
Publication of ATE366121T1 publication Critical patent/ATE366121T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT99903557T 1998-02-03 1999-02-03 Systemische verabreichung von serum-stabilen plasmid-lipid partikeln zur krebstherapie ATE366121T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7359898P 1998-02-03 1998-02-03
US8691798P 1998-05-27 1998-05-27
US10142998P 1998-09-22 1998-09-22
US11238498P 1998-12-14 1998-12-14
US24310299A 1999-02-02 1999-02-02

Publications (1)

Publication Number Publication Date
ATE366121T1 true ATE366121T1 (de) 2007-07-15

Family

ID=27535971

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99903557T ATE366121T1 (de) 1998-02-03 1999-02-03 Systemische verabreichung von serum-stabilen plasmid-lipid partikeln zur krebstherapie

Country Status (7)

Country Link
EP (1) EP1053023B2 (de)
JP (1) JP2002502831A (de)
AT (1) ATE366121T1 (de)
AU (1) AU749881B2 (de)
CA (2) CA2321837C (de)
DE (1) DE69936444T3 (de)
WO (2) WO1999039741A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2317549C (en) 1998-01-05 2006-04-11 University Of Washington Composition for enhancing transport through lipid-containing membranes, and uses thereof
CN1278739C (zh) * 2001-06-08 2006-10-11 中国人民解放军第四军医大学 包含抗人***蛋白单链抗体/人羧肽酶a融合蛋白及前体药物的药盒
WO2003049764A1 (en) 2001-12-12 2003-06-19 Fh Faulding & Co Limited Composition for viral preservation
WO2003093303A1 (en) 2002-05-06 2003-11-13 Board Of Regents, The University Of Texas System Targeting proteins to deliver therapeutic or diagnostic reagents
EP3532103A1 (de) 2016-10-26 2019-09-04 Acuitas Therapeutics, Inc. Lipidnanopartikelformulierung
WO2018191719A1 (en) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipid delivery of therapeutic agents to adipose tissue
WO2019089828A1 (en) 2017-10-31 2019-05-09 Acuitas Therapeutics, Inc. Lamellar lipid nanoparticles
EP3852911A2 (de) 2018-09-21 2021-07-28 Acuitas Therapeutics, Inc. Systeme und verfahren zur herstellung von lipidnanopartikeln und liposomen
CR20220108A (es) 2019-08-14 2022-05-27 Acuitas Therapeutics Inc Nanopartículas lipídicas mejoradas para el suministro de ácidos nucleicos
EP4126947A1 (de) 2020-03-30 2023-02-08 BioNTech SE Gegen claudin-18 gerichtete rna-zusammensetzungen.2
IL299094A (en) 2020-06-15 2023-02-01 Res Inst Nationwide Childrens Hospital Administration of an adeno-associated virus vector for muscular dystrophies
EP4319803A1 (de) 2021-04-08 2024-02-14 Vaxthera SAS Coronavirus-impfstoff, der ein mosaikprotein enthält
WO2023023055A1 (en) 2021-08-16 2023-02-23 Renagade Therapeutics Management Inc. Compositions and methods for optimizing tropism of delivery systems for rna
TW202325263A (zh) 2021-09-14 2023-07-01 美商雷納嘉德醫療管理公司 非環狀脂質及其使用方法
WO2023044333A1 (en) 2021-09-14 2023-03-23 Renagade Therapeutics Management Inc. Cyclic lipids and methods of use thereof
CA3237482A1 (en) 2021-11-03 2023-05-11 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Precise genome editing using retrons
WO2023091490A1 (en) 2021-11-16 2023-05-25 Senda Biosciences, Inc. Novel ionizable lipids and lipid nanoparticles and methods of using the same
WO2023091787A1 (en) 2021-11-22 2023-05-25 Senda Biosciences, Inc. Novel ionizable lipids and lipid nanoparticles and methods of using the same
WO2023122752A1 (en) 2021-12-23 2023-06-29 Renagade Therapeutics Management Inc. Constrained lipids and methods of use thereof
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2023147090A1 (en) 2022-01-27 2023-08-03 BioNTech SE Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
WO2023183616A1 (en) 2022-03-25 2023-09-28 Senda Biosciences, Inc. Novel ionizable lipids and lipid nanoparticles and methods of using the same
WO2023196931A1 (en) 2022-04-07 2023-10-12 Renagade Therapeutics Management Inc. Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
WO2023218431A1 (en) 2022-05-13 2023-11-16 BioNTech SE Rna compositions targeting hiv
WO2023230295A1 (en) 2022-05-25 2023-11-30 BioNTech SE Rna compositions for delivery of monkeypox antigens and related methods
WO2023232747A1 (en) 2022-05-30 2023-12-07 BioNTech SE Complexes for delivery of nucleic acids
WO2024049979A2 (en) 2022-08-31 2024-03-07 Senda Biosciences, Inc. Novel ionizable lipids and lipid nanoparticles and methods of using the same
WO2024064934A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of plasmodium csp antigens and related methods
WO2024063788A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
WO2024063789A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
WO2024064931A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of liver stage antigens and related methods
WO2024074634A1 (en) 2022-10-06 2024-04-11 BioNTech SE Rna compositions targeting claudin-18.2
WO2024074211A1 (en) 2022-10-06 2024-04-11 BioNTech SE Rna compositions targeting claudin-18.2

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
EP0800830A3 (de) * 1989-11-03 1999-03-17 Vanderbilt University Verfahren zur in Vivo-Verabreichung von funktionellen fremden Genen
EP0625207A1 (de) 1991-12-17 1994-11-23 The Regents Of The University Of California Gentherapie zur behandlung der regulatoraktivität der transmembranen leitfähigkeit bei der zytischen fibrose (cftr)
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
AU4528493A (en) 1992-06-04 1994-01-04 Regents Of The University Of California, The In vivo gene therapy with intron-free sequence of interest
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
AU705889B2 (en) * 1993-08-26 1999-06-03 Regents Of The University Of California, The Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory peptides
CN1309833C (zh) 1994-04-26 2007-04-11 儿童医学中心公司 血管生成抑制素及其在制备药物中的用途
GB9415167D0 (en) 1994-07-27 1994-09-14 Springer Caroline J Improvements relating to cancer therapy
GB9501052D0 (en) 1995-01-19 1995-03-08 Cancer Res Campaign Tech Improvements relating to prodrugs
US5705385A (en) 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
ATE285477T1 (de) * 1995-06-07 2005-01-15 Inex Pharmaceutical Corp Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer
US7517858B1 (en) * 1995-06-07 2009-04-14 The Regents Of The University Of California Prodrugs of pharmaceuticals with improved bioavailability
GB9517001D0 (en) 1995-08-18 1995-10-18 Denny William Enediyne compounds
CN1202932A (zh) 1995-10-23 1998-12-23 儿童医学中心公司 治疗用抗血管生成的组合物和方法
GB9523703D0 (en) 1995-11-20 1996-01-24 Wellcome Found Enzyme prodrug thearapy
US6347397B1 (en) 1999-03-29 2002-02-12 International Business Machines Corporation System, method, and program for providing an object-oriented install architecture
US8266598B2 (en) 2008-05-05 2012-09-11 Microsoft Corporation Bounding resource consumption using abstract interpretation

Also Published As

Publication number Publication date
CA2321837A1 (en) 1999-08-12
WO1999039740A2 (en) 1999-08-12
WO1999039741A3 (en) 1999-09-30
AU749881B2 (en) 2002-07-04
DE69936444D1 (de) 2007-08-16
EP1053023A2 (de) 2000-11-22
WO1999039740A9 (en) 1999-11-25
DE69936444T3 (de) 2012-05-10
EP1053023B1 (de) 2007-07-04
EP1053023B2 (de) 2011-03-30
WO1999039740A3 (en) 1999-10-28
CA2319468A1 (en) 1999-08-12
JP2002502831A (ja) 2002-01-29
WO1999039740A8 (en) 1999-09-23
WO1999039741A2 (en) 1999-08-12
CA2321837C (en) 2011-08-16
DE69936444T2 (de) 2008-03-20
AU2405799A (en) 1999-08-23

Similar Documents

Publication Publication Date Title
ATE366121T1 (de) Systemische verabreichung von serum-stabilen plasmid-lipid partikeln zur krebstherapie
ATE196844T1 (de) Zusammensetzungen die konjugate von cis- docosahexaenoic-säure und taxotere enthalten
HK1022301A1 (en) Conjugates of cisdocosahexaenoic acid and paclitaxel
AU2592600A (en) Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
MX9709915A (es) Heterociclos de peptidilo y composiciones que los contienen, utiles en el tratamiento de trastornos relacionados con trombina, y uso de los mismos.
PT623134E (pt) Complexos metalicos de texafirinas soluveis em agua
NO985574L (no) FremgangsmÕter og preparater anvendelige for inhibering av angiogenese
HK1030625A1 (en) Methods and compositions for immunomodulation
CA2301032A1 (en) A method of preventing or treating estrogen-dependent diseases and disorders
HK1050860A1 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
CY2431B1 (en) Novel phenanthridines substituted in the 6 position.
IL141686A0 (en) Methods of treating hypertension and compositions for use therein
MXPA04003674A (es) Uso mejorado de compuesto antitumoral en terapia de cancer.
DE69815310D1 (de) Zubereitungen zur tumorbehandlung enthaltend hai-knorpelextrakte und antineoplastische mittel
EP1421174A4 (de) E-selectin/l-selectin-liganden-polypeptide hämatopoetischer zellen und verfahren zu deren verwendung
BG103832A (en) Leptin as tumour cells proliferation inhibitor
DE69821498D1 (de) Verwendung von amifostin
DE69720783D1 (de) Reaktive sauerstoffverbindungen enthaltende verbindungen zur induzierung von zelldifferentiation maligner zellen so wie leukämie
DE69633178D1 (de) Eisenverbindungen, zusammensetzungen, herstellungsverfahren und verwendungen davon
IL141550A0 (en) Methods and compositions for the prevention or treatment of cancer
NO20002804D0 (no) Konjugater som kan anvendes ved behandling av prostatakreft
IL114382A (en) Lymphotoxin for use as a medicament for cancer therapy and use thereof in the manufacture of such medicament
EP1349485A4 (de) Zusammensetzungen und verfahren zur therapie und diagnose des ovarialkarzinoms
DE60332864D1 (de) Cd55-interaktionspartner und dessen anwendung
ZA9810974B (en) Conjugates useful in the treatment of prostate cancer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties